甲狀腺微小乳頭狀癌淋巴結轉移特點及處理策略_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 朱精強 , 雷建勇 , 姜可

四川大學華西醫院甲狀（旁）腺疾病診治中心（四川成都 610041）;

Corresponding?author：

朱精強, Email: zjq-wkys@163.com

Keywords：

DOI：

10.7507/1007-9424.20160298

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 朱精強, 雷建勇, 姜可. 甲狀腺微小乳頭狀癌淋巴結轉移特點及處理策略. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(10): 1160-1165. doi: 10.7507/1007-9424.20160298 Copy

1.	McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet, 2013, 381(9871):1046-1057.
2.	Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26(1):1-133.
3.	Lee JH, Shin SW. Overdiagnosis and screening for thyroid cancer in Korea. Lancet, 2014, 384(9957):1848.
4.	Park SH, Lee B, Lee S, et al. A qualitative study of women's views on overdiagnosis and screening for thyroid cancer in Korea. BMC Cancer, 2015, 15:858.
5.	Mehanna H, Al-Maqbili T, Carter B, et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma:a systematic review and meta-analysis of 21329 person-years of follow-up. J Clin Endocrinol Metab, 2014, 99(8):2834-2843.
6.	高明. 甲狀腺癌的診療進展及策略. 中華耳鼻咽喉頭頸外科雜志, 2010, 45(11):887-890.
7.	Zhou YL, Gao EL, Zhang W, et al. Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis:a retrospective study. World J Surg Oncol, 2012, 10:67.
8.	Lee CR, Son H, Lee S, et al. Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma:do involved lymph nodes mandate completion thyroidectomy? World J Surg, 2014, 38(4):872-877.
9.	Caliskan M, Park JH, Jeong JS, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. Endocr J, 2012, 59(4):305-311.
10.	彭冬梅, 晏晨, 蘇安平, 等. cN0甲狀腺微小乳頭狀癌右側喉返神經淺面及深面淋巴結轉移危險因素分析.中國實用外科雜志, 2016, 36(5):547-551.
11.	Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer, 2005, 103(11):p. 2269-2273.
12.	Machens A, Hinze R, Thomusch O, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg, 2002, 26(1):22-28.
13.	Kim EK, Yoon JH, Han KH, et al. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg, 2013, 37(2):385-391.
14.	Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol, 2014, 7(9):6199-6205.
15.	Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients. J Clin Endocrinol Metab, 2012, 97(4):1250-1257.
16.	Lee KJ, Cho YJ, Kim SJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg, 2011, 35(2):318-323.
17.	Park JP, Roh JL, Lee JH, et al. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma. Am J Surg, 2014, 208(3):412-418.
18.	Al Afif A, Williams BA, Rigby MH, et al. Multifocal papillary thyroid cancer increases the risk of central lymph node metastasis. Thyroid, 2015, 25(9):1008-1012.
19.	Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer, 1992, 70(6):1585-1590.
20.	Salter KD, Andersen PE, Cohen JI, et al. Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality. Arch Otolaryngol Head Neck Surg, 2010, 136(7):692-696.
21.	Hyun SM, Song HY, Kim SY, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. Ann Surg Oncol, 2012, 19(2):591-596.
22.	Lee SH, Lee SS, Jin SM, et al. Predictive factors for central compartment lymph node metastasis in thyroid papillary microcarcinoma. Laryngoscope, 2008, 118(4):659-662.
23.	Arora N, Turbendian HK, Kato MA, et al. Papillary thyroid carcinoma and microcarcinoma:is there a need to distinguish the two? Thyroid, 2009, 19(5):473-477.
24.	Mercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid:results of a study in 445 patients. Thyroid, 2009, 19(7):707-716.
25.	Besic N, Pilko G, Petric R, et al. Papillary thyroid microcarcinoma:prognostic factors and treatment. J Surg Oncol, 2008, 97(3):221-225.
26.	Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarcinoma:extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg, 2010, 34(6):1214-1221.
27.	Moon HJ, Kim EK, Chung WY, et al. Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma:is it a real prognostic factor? Ann Surg Oncol, 2011, 18(7):1916-1923.
28.	Mohebati A, Shaha AR. Anatomy of thyroid and parathyroid glands and neurovascular relations. Clin Anat, 2012, 25(1):19-31.
29.	Suman P, Wang CH, Abadin SS, et al. Risk factors for central lymph node metastasis in papillary thyroid carcinoma:A National Cancer Data Base (NCDB) study. Surgery, 2016, 159(1):31-39.
30.	Kwak JY, Kim EK, Kim MJ, et al. Papillary microcarcinoma of the thyroid:predicting factors of lateral neck node metastasis. Ann Surg Oncol, 2009, 16(5):1348-1355.
31.	Lee YS, Shin SC, Lim YS, et al. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck, 2014, 36(6):887-891.
32.	Karatzas T, Charitoudis G, Vasileiadis D, et al. Surgical treatment for dominant malignant nodules of the isthmus of the thyroid gland:A case control study. Int J Surg, 2015, 18:64-68.
33.	Lee YS, Jeong JJ, Nam KH, et al. Papillary carcinoma located in the thyroid isthmus. World J Surg, 2010, 34(1):36-39.
34.	Lei JY, Zhu JQ, Li ZH, et al. Surgical procedures for papillary thyroid carcinoma located in the thyroid isthmus:an intention-to-treat analysis. Onco Targets Ther, 2016, 9:5209-5216.
35.	Xing M, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. Jama, 2013, 309(14):1493-1501.
36.	Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014, 159(3):676-690.
37.	Li F, Chen G, Sheng C, et al. BRAFV600E mutation in papillary thyroid microcarcinoma:a meta-analysis. Endocr Relat Cancer, 2015, 22(2):159-168.
38.	Ma YJ, Deng XL, Li HQ. BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma:A meta-analysis. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(4):591-599.
39.	Park VY, Kim EK, Lee HS,et al. Real-time PCR cycle threshold values for the BRAFV600E mutation in papillary thyroid microcarcinoma may be associated with central lymph node metastasis:a retrospective study. Medicine (Baltimore), 2015, 94(28):e1149.
40.	Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010, 17(12):3294-300.
41.	Liu C, Chen T, Liu Z. Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma:a meta-analysis. World J Surg Oncol, 2016, 14(1):241.
42.	Lee SE, Hwang TS, Choi YL, et al. Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAFV600E mutation-prevalent population. Thyroid, 2016, 26(7):901-910.
43.	Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAFV600E and TERT promoter mutations in papillary thyroid cancer:genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol, 2016,[Epub ahead of print].
44.	Silver CE, Owen RP, Rodrigo JP, et al. Aggressive variants of papillary thyroid carcinoma. HeadNeck, 2011, 33(7):1052-1059.
45.	Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, et al. Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid:an analysis of rhabdoid and thyroglobulin inclusions. Am J Surg Pathol, 2007, 31(5):729-736.
46.	Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol, 2004, 86(1):44-54.
47.	Dobrinja C, Makovac P, Pastoricchio M, et al. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome. Int J Surg, 2016, 28 Suppl 1:S70-S74.
48.	Jara SM, Carson KA, Pai SI, et al. The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. Surgery, 2013. 154(6):1272-1280; discussion 1280-1282.
49.	Zhu Y, Zheng K, Zhang H, et al. The clinicopathologic differences of central lymph node metastasis in predicting lateral lymph node metastasis and prognosis in papillary thyroid cancer associated with or without Hashimoto's thyroiditis. Tumour Biol, 2016, 37(6):8037-8045.
50.	Qu N, Zhang L, Lin DZ, et al. The impact of coexistent Hashimoto's thyroiditis on lymph node metastasis and prognosis in papillary thyroid microcarcinoma. Tumour Biol, 2016, 37(6):7685-7692.
51.	Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg, 1996, 83(12):1674-1683.
52.	Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer, 1985, 56(3):531-538.
53.	Pelizzo MR, Boschin IM, Toniato A, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC):a mono-institutional 12-year experience. Nucl Med Commun, 2004, 25(6):547-552.
54.	Roh JL, Kim JM, Park CI. Lateral cervical lymph node metastases from papillary thyroid carcinoma:pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol, 2008, 15(4):1177-1182.
55.	Kim YS. Patterns and predictive factors of lateral lymph node metastasis in papillary thyroid microcarcinoma. Otolaryngol Head Neck Surg, 2012, 147(1):15-19.
56.	Kim SK, Park I, Woo JW, et al. Predictive factors for lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol, 2016, 23(9):2866-2873.
57.	Machens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery, 2009, 145(2):176-181.
58.	Zeng RC, Zhang W, Gao EL, et al. Number of central lymph node metastasis for predicting lateral lymph node metastasis in papillary thyroid microcarcinoma. Head Neck, 2014, 36(1):101-106.
59.	Xiao GZ, Gao L. Central lymph node metastasis:is it a reliable indicator of lateral node involvement in papillary thyroid carcinoma? World J Surg, 2010, 34(2):237-241.
60.	陳銳, 魏濤, 張明, 等. 甲狀腺乳頭狀癌cN0患者頸側區淋巴結轉移規律的探討.中華耳鼻咽喉頭頸外科雜志, 2012, 47(8):662-667.
61.	Lan X, Sun W, Zhang H, et al. A meta-analysis of central lymph node metastasis for predicting lateral involvement in papillary thyroid carcinoma. Otolaryngol Head Neck Surg, 2015, 153(5):731-738.
62.	吳毅. 分化型甲狀腺癌診治中值得關注的一些問題. 中國實用外科雜志, 2011, 31(5):374-375.
63.	Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery, 2011, 150(6):1048-1057.
64.	Onkendi EO, McKenzie TJ, Richards ML, et al. Reoperative experience with papillary thyroid cancer. World J Surg, 2014, 38(3):645-652.
65.	Kim MK, Mandel SH, Baloch Z, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg, 2004, 130(10):1214-1216.
66.	Lefevre JH, Tresallet C, Leenhardt L, et al. Reoperative surgery for thyroid disease. Langenbecks Arch Surg, 2007, 392(6):685-691.
67.	Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg, 2016,[Epub ahead of print].
68.	Al-Qurayshi Z, Robins R, Hauch A, et al. Association of surgeon volume with outcomes and cost savings following thyroidectomy:a national forecast. JAMA Otolaryngol Head Neck Surg, 2016, 142(1):32-39.
69.	Robbins KT, Medina JE, Wolfe GT, et al. Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology. Arch Otolaryngol Head Neck Surg, 1991, 117(6):601-605.
70.	Bae SY, Yang JH, Choi MY, et al. Right paraesophageal lymph node dissection in papillary thyroid carcinoma. Ann Surg Oncol, 2012, 19(3):996-1000.
71.	朱精強, 分化型甲狀腺癌頸淋巴結清掃的相關問題.中國普外基礎與臨床雜志, 2012, 19(8):809-813.
72.	Roh JL, Kim JM, Park CI. Central cervical nodal metastasis from papillary thyroid microcarcinoma:pattern and factors predictive of nodal metastasis. Ann Surg Oncol, 2008, 15(9):2482-2486.
73.	黃輝,徐震綱, 王曉雷, 等. 淋巴結臨床陰性甲狀腺乳頭狀癌中央區淋巴結清掃后頸部復發模式分析.中華腫瘤雜志, 2015,37(10):771-775.
74.	Xue S, Wang PS, Liu J, et al. Prophylactic central lymph node dissection in cN0 patients with papillary thyroid carcinoma:A retrospective study in China. Asian J Surg, 2016, 39(3):131-136.
75.	Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery, 2003, 134(6):946-954, discussion 954-955.
76.	Ahn JE, Lee JH, Yi JS, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg, 2008, 32(7):1552-1558.
77.	Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope, 2011, 121(3):487-491.
78.	Moo TA, McGill J, Allendorf J, et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg, 2010, 34(6):1187-1191.
79.	Perrino M, Vannucchi G, Vicentini L, et al. Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or=2 cm. Endocr Relat Cancer, 2009, 16(1):201-210.
80.	中國抗癌協會甲狀腺癌專業委員會. 甲狀腺微小乳頭狀癌診斷與治療中國專家共識(2016版). 中國腫瘤臨床, 2016. 43(10):405-411.
81.	Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
82.	Kim WW, Yang SI, Kim JH, et al. Experience and analysis of Delphian lymph node metastasis in patients with papillary thyroid carcinoma. World J Surg Oncol, 2012, 10:226.
83.	Lee YC, Shin SY, Kwon KH, et al. Incidence and clinical characteristics of prelaryngeal lymph node metastasis in papillary thyroid cancer. Eur Arch Otorhinolaryngol, 2013, 270(9):2547-2550.
84.	Oh EM, Chung YS, Lee YD. Clinical significance of Delphian lymph node metastasis in papillary thyroid carcinoma. World J Surg, 2013, 37(11):2594-2599.
85.	Keum HS, Ji YB, Kim JM, et al. Optimal surgical extent of lateral and central neck dissection for papillary thyroid carcinoma located in one lobe with clinical lateral lymph node metastasis. World J Surg Oncol, 2012, 10:221.
86.	龔艷萍, 龔日祥, 朱精強, 等. cN0甲狀腺乳頭狀癌中央區淋巴結清掃策略的臨床研究. 中華外科雜志, 2013, 51(12):1081-1084.
87.	中華醫學會內分泌學分會. 甲狀腺結節和分化型甲狀腺癌診治指南. 中國腫瘤臨床, 2012. 33(17):1249-1272.
88.	趙曉偉, 關海霞, 孫輝. 頸部淋巴結細針穿刺針洗脫液甲狀腺球蛋白測定臨床應用進展與困惑. 中國實用內科雜志, 2016, 36(1):37-40.
89.	許立龍, 李世巖, 徐海珊. 高頻超聲引導下細針抽吸活檢結合細針抽吸洗脫液甲狀腺球蛋白檢測對甲狀腺乳頭狀癌術后頸部淋巴結轉移的診斷價值.中華超聲影像學雜志, 2014, 23(8):679-682.

1. McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet, 2013, 381(9871):1046-1057.
2. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26(1):1-133.
3. Lee JH, Shin SW. Overdiagnosis and screening for thyroid cancer in Korea. Lancet, 2014, 384(9957):1848.
4. Park SH, Lee B, Lee S, et al. A qualitative study of women's views on overdiagnosis and screening for thyroid cancer in Korea. BMC Cancer, 2015, 15:858.
5. Mehanna H, Al-Maqbili T, Carter B, et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma:a systematic review and meta-analysis of 21329 person-years of follow-up. J Clin Endocrinol Metab, 2014, 99(8):2834-2843.
6. 高明. 甲狀腺癌的診療進展及策略. 中華耳鼻咽喉頭頸外科雜志, 2010, 45(11):887-890.
7. Zhou YL, Gao EL, Zhang W, et al. Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis:a retrospective study. World J Surg Oncol, 2012, 10:67.
8. Lee CR, Son H, Lee S, et al. Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma:do involved lymph nodes mandate completion thyroidectomy? World J Surg, 2014, 38(4):872-877.
9. Caliskan M, Park JH, Jeong JS, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. Endocr J, 2012, 59(4):305-311.
10. 彭冬梅, 晏晨, 蘇安平, 等. cN0甲狀腺微小乳頭狀癌右側喉返神經淺面及深面淋巴結轉移危險因素分析.中國實用外科雜志, 2016, 36(5):547-551.
11. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer, 2005, 103(11):p. 2269-2273.
12. Machens A, Hinze R, Thomusch O, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg, 2002, 26(1):22-28.
13. Kim EK, Yoon JH, Han KH, et al. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg, 2013, 37(2):385-391.
14. Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol, 2014, 7(9):6199-6205.
15. Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients. J Clin Endocrinol Metab, 2012, 97(4):1250-1257.
16. Lee KJ, Cho YJ, Kim SJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg, 2011, 35(2):318-323.
17. Park JP, Roh JL, Lee JH, et al. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma. Am J Surg, 2014, 208(3):412-418.
18. Al Afif A, Williams BA, Rigby MH, et al. Multifocal papillary thyroid cancer increases the risk of central lymph node metastasis. Thyroid, 2015, 25(9):1008-1012.
19. Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer, 1992, 70(6):1585-1590.
20. Salter KD, Andersen PE, Cohen JI, et al. Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality. Arch Otolaryngol Head Neck Surg, 2010, 136(7):692-696.
21. Hyun SM, Song HY, Kim SY, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. Ann Surg Oncol, 2012, 19(2):591-596.
22. Lee SH, Lee SS, Jin SM, et al. Predictive factors for central compartment lymph node metastasis in thyroid papillary microcarcinoma. Laryngoscope, 2008, 118(4):659-662.
23. Arora N, Turbendian HK, Kato MA, et al. Papillary thyroid carcinoma and microcarcinoma:is there a need to distinguish the two? Thyroid, 2009, 19(5):473-477.
24. Mercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid:results of a study in 445 patients. Thyroid, 2009, 19(7):707-716.
25. Besic N, Pilko G, Petric R, et al. Papillary thyroid microcarcinoma:prognostic factors and treatment. J Surg Oncol, 2008, 97(3):221-225.
26. Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarcinoma:extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg, 2010, 34(6):1214-1221.
27. Moon HJ, Kim EK, Chung WY, et al. Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma:is it a real prognostic factor? Ann Surg Oncol, 2011, 18(7):1916-1923.
28. Mohebati A, Shaha AR. Anatomy of thyroid and parathyroid glands and neurovascular relations. Clin Anat, 2012, 25(1):19-31.
29. Suman P, Wang CH, Abadin SS, et al. Risk factors for central lymph node metastasis in papillary thyroid carcinoma:A National Cancer Data Base (NCDB) study. Surgery, 2016, 159(1):31-39.
30. Kwak JY, Kim EK, Kim MJ, et al. Papillary microcarcinoma of the thyroid:predicting factors of lateral neck node metastasis. Ann Surg Oncol, 2009, 16(5):1348-1355.
31. Lee YS, Shin SC, Lim YS, et al. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck, 2014, 36(6):887-891.
32. Karatzas T, Charitoudis G, Vasileiadis D, et al. Surgical treatment for dominant malignant nodules of the isthmus of the thyroid gland:A case control study. Int J Surg, 2015, 18:64-68.
33. Lee YS, Jeong JJ, Nam KH, et al. Papillary carcinoma located in the thyroid isthmus. World J Surg, 2010, 34(1):36-39.
34. Lei JY, Zhu JQ, Li ZH, et al. Surgical procedures for papillary thyroid carcinoma located in the thyroid isthmus:an intention-to-treat analysis. Onco Targets Ther, 2016, 9:5209-5216.
35. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. Jama, 2013, 309(14):1493-1501.
36. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014, 159(3):676-690.
37. Li F, Chen G, Sheng C, et al. BRAFV600E mutation in papillary thyroid microcarcinoma:a meta-analysis. Endocr Relat Cancer, 2015, 22(2):159-168.
38. Ma YJ, Deng XL, Li HQ. BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma:A meta-analysis. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(4):591-599.
39. Park VY, Kim EK, Lee HS,et al. Real-time PCR cycle threshold values for the BRAFV600E mutation in papillary thyroid microcarcinoma may be associated with central lymph node metastasis:a retrospective study. Medicine (Baltimore), 2015, 94(28):e1149.
40. Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010, 17(12):3294-300.
41. Liu C, Chen T, Liu Z. Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma:a meta-analysis. World J Surg Oncol, 2016, 14(1):241.
42. Lee SE, Hwang TS, Choi YL, et al. Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAFV600E mutation-prevalent population. Thyroid, 2016, 26(7):901-910.
43. Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAFV600E and TERT promoter mutations in papillary thyroid cancer:genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol, 2016,[Epub ahead of print].
44. Silver CE, Owen RP, Rodrigo JP, et al. Aggressive variants of papillary thyroid carcinoma. HeadNeck, 2011, 33(7):1052-1059.
45. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, et al. Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid:an analysis of rhabdoid and thyroglobulin inclusions. Am J Surg Pathol, 2007, 31(5):729-736.
46. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol, 2004, 86(1):44-54.
47. Dobrinja C, Makovac P, Pastoricchio M, et al. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome. Int J Surg, 2016, 28 Suppl 1:S70-S74.
48. Jara SM, Carson KA, Pai SI, et al. The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. Surgery, 2013. 154(6):1272-1280; discussion 1280-1282.
49. Zhu Y, Zheng K, Zhang H, et al. The clinicopathologic differences of central lymph node metastasis in predicting lateral lymph node metastasis and prognosis in papillary thyroid cancer associated with or without Hashimoto's thyroiditis. Tumour Biol, 2016, 37(6):8037-8045.
50. Qu N, Zhang L, Lin DZ, et al. The impact of coexistent Hashimoto's thyroiditis on lymph node metastasis and prognosis in papillary thyroid microcarcinoma. Tumour Biol, 2016, 37(6):7685-7692.
51. Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg, 1996, 83(12):1674-1683.
52. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer, 1985, 56(3):531-538.
53. Pelizzo MR, Boschin IM, Toniato A, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC):a mono-institutional 12-year experience. Nucl Med Commun, 2004, 25(6):547-552.
54. Roh JL, Kim JM, Park CI. Lateral cervical lymph node metastases from papillary thyroid carcinoma:pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol, 2008, 15(4):1177-1182.
55. Kim YS. Patterns and predictive factors of lateral lymph node metastasis in papillary thyroid microcarcinoma. Otolaryngol Head Neck Surg, 2012, 147(1):15-19.
56. Kim SK, Park I, Woo JW, et al. Predictive factors for lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol, 2016, 23(9):2866-2873.
57. Machens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery, 2009, 145(2):176-181.
58. Zeng RC, Zhang W, Gao EL, et al. Number of central lymph node metastasis for predicting lateral lymph node metastasis in papillary thyroid microcarcinoma. Head Neck, 2014, 36(1):101-106.
59. Xiao GZ, Gao L. Central lymph node metastasis:is it a reliable indicator of lateral node involvement in papillary thyroid carcinoma? World J Surg, 2010, 34(2):237-241.
60. 陳銳, 魏濤, 張明, 等. 甲狀腺乳頭狀癌cN0患者頸側區淋巴結轉移規律的探討.中華耳鼻咽喉頭頸外科雜志, 2012, 47(8):662-667.
61. Lan X, Sun W, Zhang H, et al. A meta-analysis of central lymph node metastasis for predicting lateral involvement in papillary thyroid carcinoma. Otolaryngol Head Neck Surg, 2015, 153(5):731-738.
62. 吳毅. 分化型甲狀腺癌診治中值得關注的一些問題. 中國實用外科雜志, 2011, 31(5):374-375.
63. Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery, 2011, 150(6):1048-1057.
64. Onkendi EO, McKenzie TJ, Richards ML, et al. Reoperative experience with papillary thyroid cancer. World J Surg, 2014, 38(3):645-652.
65. Kim MK, Mandel SH, Baloch Z, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg, 2004, 130(10):1214-1216.
66. Lefevre JH, Tresallet C, Leenhardt L, et al. Reoperative surgery for thyroid disease. Langenbecks Arch Surg, 2007, 392(6):685-691.
67. Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg, 2016,[Epub ahead of print].
68. Al-Qurayshi Z, Robins R, Hauch A, et al. Association of surgeon volume with outcomes and cost savings following thyroidectomy:a national forecast. JAMA Otolaryngol Head Neck Surg, 2016, 142(1):32-39.
69. Robbins KT, Medina JE, Wolfe GT, et al. Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology. Arch Otolaryngol Head Neck Surg, 1991, 117(6):601-605.
70. Bae SY, Yang JH, Choi MY, et al. Right paraesophageal lymph node dissection in papillary thyroid carcinoma. Ann Surg Oncol, 2012, 19(3):996-1000.
71. 朱精強, 分化型甲狀腺癌頸淋巴結清掃的相關問題.中國普外基礎與臨床雜志, 2012, 19(8):809-813.
72. Roh JL, Kim JM, Park CI. Central cervical nodal metastasis from papillary thyroid microcarcinoma:pattern and factors predictive of nodal metastasis. Ann Surg Oncol, 2008, 15(9):2482-2486.
73. 黃輝,徐震綱, 王曉雷, 等. 淋巴結臨床陰性甲狀腺乳頭狀癌中央區淋巴結清掃后頸部復發模式分析.中華腫瘤雜志, 2015,37(10):771-775.
74. Xue S, Wang PS, Liu J, et al. Prophylactic central lymph node dissection in cN0 patients with papillary thyroid carcinoma:A retrospective study in China. Asian J Surg, 2016, 39(3):131-136.
75. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery, 2003, 134(6):946-954, discussion 954-955.
76. Ahn JE, Lee JH, Yi JS, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg, 2008, 32(7):1552-1558.
77. Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope, 2011, 121(3):487-491.
78. Moo TA, McGill J, Allendorf J, et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg, 2010, 34(6):1187-1191.
79. Perrino M, Vannucchi G, Vicentini L, et al. Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or=2 cm. Endocr Relat Cancer, 2009, 16(1):201-210.
80. 中國抗癌協會甲狀腺癌專業委員會. 甲狀腺微小乳頭狀癌診斷與治療中國專家共識(2016版). 中國腫瘤臨床, 2016. 43(10):405-411.
81. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
82. Kim WW, Yang SI, Kim JH, et al. Experience and analysis of Delphian lymph node metastasis in patients with papillary thyroid carcinoma. World J Surg Oncol, 2012, 10:226.
83. Lee YC, Shin SY, Kwon KH, et al. Incidence and clinical characteristics of prelaryngeal lymph node metastasis in papillary thyroid cancer. Eur Arch Otorhinolaryngol, 2013, 270(9):2547-2550.
84. Oh EM, Chung YS, Lee YD. Clinical significance of Delphian lymph node metastasis in papillary thyroid carcinoma. World J Surg, 2013, 37(11):2594-2599.
85. Keum HS, Ji YB, Kim JM, et al. Optimal surgical extent of lateral and central neck dissection for papillary thyroid carcinoma located in one lobe with clinical lateral lymph node metastasis. World J Surg Oncol, 2012, 10:221.
86. 龔艷萍, 龔日祥, 朱精強, 等. cN0甲狀腺乳頭狀癌中央區淋巴結清掃策略的臨床研究. 中華外科雜志, 2013, 51(12):1081-1084.
87. 中華醫學會內分泌學分會. 甲狀腺結節和分化型甲狀腺癌診治指南. 中國腫瘤臨床, 2012. 33(17):1249-1272.
88. 趙曉偉, 關海霞, 孫輝. 頸部淋巴結細針穿刺針洗脫液甲狀腺球蛋白測定臨床應用進展與困惑. 中國實用內科雜志, 2016, 36(1):37-40.
89. 許立龍, 李世巖, 徐海珊. 高頻超聲引導下細針抽吸活檢結合細針抽吸洗脫液甲狀腺球蛋白檢測對甲狀腺乳頭狀癌術后頸部淋巴結轉移的診斷價值.中華超聲影像學雜志, 2014, 23(8):679-682.

Previous Article
甲狀腺椎體葉乳頭狀癌伴側頸區淋巴結跳躍性轉移1例報道
Next Article
2015年版較2009年版ATA指南對甲狀腺乳頭狀癌的手術治療變化及解讀

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

甲狀腺微小乳頭狀癌淋巴結轉移特點及處理策略

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content